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Abstract
Macrophages (MWs) determine oral mucosal responses; mediating tolerance to commensal microbes and food whilst
maintaining the capacity to activate immune defences to pathogens. MW responses are determined by both differentiation
and activation stimuli, giving rise to two distinct subsets; pro-inflammatory M1- and anti-inflammatory/regulatory M2- MWs.
M2-like subsets predominate tolerance induction whereas M1 MWs predominate in inflammatory pathologies, mediating
destructive inflammatory mechanisms, such as those in chronic P.gingivalis (PG) periodontal infection. MW responses can be
suppressed to benefit either the host or the pathogen. Chronic stimulation by bacterial pathogen associated molecular
patterns (PAMPs), such as LPS, is well established to induce tolerance. The aim of this study was to investigate the
susceptibility of MW subsets to suppression by P. gingivalis. CD14hi and CD14lo M1- and M2-like MWs were generated in vitro
from the THP-1 monocyte cell line by differentiation with PMA and vitamin D3, respectively. MW subsets were pre-treated
with heat-killed PG (HKPG) and PG-LPS prior to stimulation by bacterial PAMPs. Modulation of inflammation was measured
by TNFa, IL-1b, IL-6, IL-10 ELISA and NFkB activation by reporter gene assay. HKPG and PG-LPS differentially suppress PAMP-
induced TNFa, IL-6 and IL-10 but fail to suppress IL-1b expression in M1 and M2 MWs. In addition, P.gingivalis suppressed
NFkB activation in CD14lo and CD14hi M2 regulatory MWs and CD14lo M1 MWs whereas CD14hi M1 pro-inflammatory MWs
were refractory to suppression. In conclusion, P.gingivalis selectively tolerises regulatory M2 MWs with little effect on pro-
inflammatory CD14hi M1 MWs; differential suppression facilitating immunopathology at the expense of immunity.
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Introduction
Chronic periodontitis (CP) is a persistent inflammatory condi-
tion of the periodontal tissues resulting in destruction of the
periodontium which, if left untreated, could result in tooth loss. CP
results as a consequence of the host inflammatory response to
persistent microbial challenge represented by a dysbiotic biofilm in
which Porphyromonas gingivalis (PG) is an important member [1–3].
PG is an intracellular oral mucosal pathogen which evades
recognition and uptake by neutrophils, infecting oral epithelial
cells, fibroblasts and underlying dendritic cells and macrophages
(MWs) [4–6]. Clearance of such intracellular pathogens would
necessitate cell mediated immunity, involving Th1 subset cells.
Porphyromonas gingivalis LPS (PG-LPS) however, predominantly
induces Th2-mediated humoral responses to extracellular patho-
gens; hence immune-deviation towards a non-clearing response is
integral to pathogen persistence [7]. PG-LPS also possesses low
endotoxin activity and targets TLR2, at the expense of the
traditional LPS receptor, TLR4, although P. gingivalis strains
exhibit differential structural LPS formats to and, as a conse-
quence, differential utilisation of both TLR2 and TLR4 [8]. Thus,
PG subverts both adaptive and innate immune function to survive
in oral mucosal tissue.
Immune subversion can be achieved by both immunomodula-
tory and immunosuppressive mechanisms. PG-LPS is able to
induce endotoxin tolerance (ET) in MWs; ET was first char-
acterised by LPS pre-exposure rendering innate immune cells
refractory to subsequent endotoxin challenge, reviewed in [9]. ET
would appear to be both beneficial and harmful to host and
pathogen alike; suppressing harmful over-exuberant tissue-de-
structive pro-inflammatory responses, manifestation of sepsis,
autoimmunity and cancer in the host [10], whereas, simulta-
neously, suppresses protective inflammatory responses mounted
against the oral pathogen. Oral mucosal MWs are important to
ET; their differentiation and activation status determining whether
the mucosal environment is beneficial to the host tissue or
pathogen. PG modulates host cell function in order to facilitate its
own survival [11,12]. Upon LPS recognition, this pathogen
induces an inflammatory response modulated by a wide range of
inflammatory molecules. Of interest however, is that PG only
weakly induces inflammatory cytokines, favouring an insufficient
clearing response, bacterial proliferation and persistence. The
cytokine production in response to this expanded bacterial number
contributes to localised tissue destruction characteristic of chronic
periodontitis [13–15].
MWs densely populate oral mucosa, responding to P.gingivalis by
producing pro-inflammatory cytokines such as TNFa, IL-1a, IL-
1b, IL-18, IL-18R, IL-18RAcp, IL1F9, IL-6, LIF, IL-12, IL-8,
CCL2, CXCL10, MCP-1 and IL-32. Conversely, expression of
anti-inflammatory cytokines (eg. IL-10) are induced, but at much
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e67955
lower levels compared to pro-inflammatory cytokines [16]. This
profile is suggestive of a MW resembling the M1 pro-inflammatory
subset. In the context of non-infected homeostatic oral mucosal
tissue, the cytokine effector phenotype resembles the anti-
inflammatory/regulatory M2 subset, reviewed in [17]. PG-LPS-
induced MW cytokine profiles are indeed suggestive of M1 subset
association with pro-inflammatory pathology whereas M2 MWs
are associated with regulatory/homeoatatic conditions. M1 MWs
are activated by LPS through TLR4, inducing NFkB -dependent
pro-inflammatory cytokines. M2 MWs however, exhibit similar
PRR expression and a different cytokine profile where pro-
inflammatory cytokine expression is relatively lower compared to
M1 MWs, reviewed in [18]. In addition, MW subsets exhibit a
differential NFkB -dependency; where M1 activity is dependent on
p65/p50 NFkB and M2 on p50/p50 NFkB [19–21], determining
responses as activatory/pro-inflammatory or tolerogenic/anti-
inflammatory. MW tolerance can be induced by several different
mechanisms: these include down-regulation of PRRs, induction of
suppressive cytokines (TGFb and IL-10) and pro-inflammatory
cytokine analogues, shedding of cytokine receptors and PRRs and
induction of endogenous inhibitors to PRR-mediated signalling
such as Tollip, Myd88s, SARM, sTLRs, sCD14 and SIGIRR.
MWs express both TLR2 and TLR4; responses to their
respective PAMPs, lipopeptides and LPS are optimised by
association with the co-receptor molecule, CD14, driving potent
inflammatory responses characterised by high levels of the pro-
inflammatory cytokines, TNFa, IL-1b, IL-6, IL-8. Indeed, CD14
gene polymorphisms are associated with inflammatory periodontal
disease, where CD14hi expression is indicative of higher levels of
inflammation [22]. CD14 expression is partially predictive of
mucosal MW effector phenotype: CD14lo MWs produce anti-
inflammatory/regulatory cytokines (TGFb and IL-10) and low
levels of pro-inflammatory cytokines [23]. As such, mucosal MWs,
existing in a non-pathogenic and homeostatic state, resemble the
M2 MW phenotype. CD14hi MWs, on the other hand, produce
high levels of pro-inflammatory- and low levels of regulatory-
cytokines: resembling M1 MWs, readily activated by PAMPs
which, if uncontrolled, drive chronic inflammatory pathology.
Thus, mucosal MW effector phenotype (inflammatory vs regula-
tory) may be controlled by regulation of TLR and CD14
expression. Of significance to control of effector phenotype is the
observation that gingipains, released from outer membrane
vesicles of P.gingivalis, have been described to cleave CD14 from
the membrane surface [24]. Such a mechanism can suppress MW
inflammatory responses (LPS hypo-responsiveness) and represents
another tolerogenic response associated with ET.
The relevance of ET in the pathology of CP is the subject of
intense research efforts. ET may benefit both the host and
pathogen; tolerance would normally be viewed as beneficial in the
context of a destructive inflammatory pathology, whereas in the
case of PG, ET may favour pathogen persistence. PG-LPS is
predominantly recognised by TLR2, instead of TLR4. In CP,
both TLR2+ and TLR4+ monocytes are recruited into the gingival
lamina propria whereas, concurrently, in diseased human CP
gingiva, mucosal tissue was generally tolerised where TLR2,
TLR4, TLR5 and MD-2 expression was down-regulated.
Functional studies substantiated these results, PG-LPS pre-
treatment of monocytes suppressed subsequent PG-LPS stimula-
tion of both pro-inflammatory (TNFa, IL-1b, IL-6, IL-8) and anti-
inflammatory cytokines (IL-10) [25]. The aim of this study was
thus two-fold: to investigate whether Porphyromonas gingivalis
differentially modulates cytokine production in the pro-inflamma-
tory M1-like MW subset in comparison to the anti-inflammatory/
regulatory M2-like subset and to expand on current understanding
of P. gingivalis-induced endotoxin tolerance in the context of these
functionally disparate MW subsets, relevant to mucosal MW
effector function.
Materials and Methods
Monocyte and macrophage (MW) culture
The human monocytic cell line, THP-1, was obtained from
ECACC and routinely used between passages 7 and 25. THP-1
cells were maintained in RPMI-1640 medium supplemented with
10% v/v foetal calf serum, 2 mM L-glutamine,100 U/ml
penicillin and 100 mg/ml streptomycin (Lonza, Wokingham,
UK), here on referred to as R10 medium. The THP-1 NFkB
reporter cell lines THP-1Blue (CD14lo) and THP-1Blue-CD14
(CD14hi) (Autogen Bioclear, Calne, UK) were maintained in R10
medium in the presence of the selection antibiotics, zeocin
(200 mg/ml) only (CD14lo) or 200 mg/ml zeocin and 10 mg/ml
blastocidin (CD14hi) (Autogen Bioclear, Calne, UK). Stable
expression status of membrane-associated CD14 as either CD14lo
or CD14hi was routinely checked by flow cytometry. Cells were
plated out at a density of 16105cells/well in R10 medium in 96
flat-bottomed well tissue culture plates (monocyte cultures). Pro-
inflammatory (M1-like) MWs and anti-inflammatory (M2-like)
MWs were generated by monocyte differentiation in the presence
of 25 ng/ml PMA or 10 nM 1,25-(OH)2-Vitamin D3 (Sigma-
Aldrich, Poole, UK) for 3 and 7 days, respectively [26].
Bacteria and pathogen associated molecular patterns
(PAMPs)
Bacterial products were obtained from Autogen Bioclear,
Calne, UK. P. gingivalis strain ATCC 33277 was originally isolated
from human gingival sulcus and obtained from the American
Type Culture Collection. Due to the ability of P.gingivalis to induce
inflammatory factors via membrane receptors and to invade
mucosal cells by phagocytosis, the effects of Porphyromonas gingivalis
lipopolysaccharide (PG-LPS) were compared to those obtained for
whole bacterial cells, heat-killed Porphyromonas gingivalis, HKPG (in
the absence of any secreted bacterial products). PG-LPS was
extracted by successive enzymatic hydrolysis and purification by
Phenol-TEA-DOC protocol, described in [27]. HKPG were
prepared by heating a bacterial suspension of P.gingivalis to 120uC
for 30 minutes followed by several washes in endotoxin-free water.
Peptidoglycan (PGN) was purchased from Sigma-Aldrich, Poole,
Dorset, UK.
Activation of monocyte and macrophage cytokine
production
THP-1, THP-1(CD14lo) and THP-1(CD14hi)-derived M1- and
M2-like MWs were stimulated by the bacterial pathogen associated
molecular patterns (PAMPs); 100 ng/ml PG-LPS, 16107cells/ml
HKPG and 10 mg/ml of the TLR2-ligand, lipoteichoic acid (LTA)
(Autogen Bioclear, Calne, UK) and cultured for 18 hours
(determined as optimal PAMP concentration and time period
for expression of all the pro-inflammatory cytokines TNFa, IL-1b
and IL-6, data not shown). Supernatants were then harvested and
either used immediately for colorimetric analysis of NFkB activity
or alternatively, stored at 220uC until required for cytokine assay
by sandwich ELISA.
Tolerisation by pre-incubation with Porphyromonas
gingivalis PAMPs, LTA and PGN
THP-1, THP-1(CD14lo) and THP-1(CD14hi)-derived M1- and
M2-like MWs were pre-treated for 24 hours with either 100 ng/ml
Macrophage Tolerisation by P. gingivalis
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PG-LPS, 16107cells/ml HKPG, 10 mg/ml LTA or 10 mg/ml
PGN (determined as the optimal concentration and time duration
for tolerisation, data not shown) or R10 medium alone (tolerisation
negative control). Pre-stimulus culture medium was carefully
removed, after which MWs were washed in fresh R10 prior to
stimulation for a further 18 hours at 37uC/5% CO2. MWs were
either stimulated with 100 ng/ml PG-LPS, 16107cells/ml HKPG,
10mg/ml LTA or R10 medium alone (stimulation negative
control). After this stimulation period, supernatants were harvested
and either used immediately for colorimetric analysis of NFkB
activity or stored at 220uC until required for cytokine assay by
sandwich ELISA. To demonstrate a physiologically-relevant
tolerisation; after stimulation or tolerisation protocols, MW
viability was routinely checked by either MTT assay or trypan
blue exclusion. No significant reductions in viability were observed
for PAMPs used in this study, viability was routinely .85%.
Cytokine measurement
Cytokines; TNFa, IL-1b, IL-6 and IL-10 were analysed by
sandwich ELISA using capture and detection antibodies commer-
Figure 1. M1 & M2 MWs display differential cytokine profiles in response to PG-LPS and HKPG. THP-1-derived M1 and M2 MWs were
generated by differentiating THP-1 monocytes with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1,25-(OH)2 vitamin D3
for 7 days, respectively. M1 (bold) and M2 (shaded) MW subsets were stimulated with either 100 ng/ml PG-LPS (a, b and c) or 16107 cells/ml HKPG (d,
e and f). Cytokine production is expressed as the mean 6 SD in pg/ml for TNFa (a & d), IL-1b (b & e) and IL-6 (c & f). Data displayed represents
triplicate samples for n = 3 replicate experiments. Significant differences in cytokine production between activated M1 and M2 MWs are indicated as
*p,0.05, **p,0.01, ***P,0.001 and ns, not significant.
doi:10.1371/journal.pone.0067955.g001
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cially available from R&D Systems UK Ltd., Abingdon and BD-
Pharmingen, Oxford, UK. Protocols were followed according to
manufacturer’s instructions and compared to standard curves,
between the range of 7 to 5,000 pg/ml, using the international
standards available from NIBSC, Potter’s Bar, UK. Colorimetric
development was measured spectrophotometrically by an OPTI-
Max tuneable microplate reader at 450 nm and analysed by
Softmax Pro version 2.4.1 software (Molecular Devices Corp.,
Sunnyvale, CA, USA).
NFkB activity measurement
NFkB activity was measured using a colorimetric reporter gene
assay for secreted embryonic alkaline phosphatase (SEAP)
associated with the stably-transfected reporter gene cell lines,
THP-1Blue (CD14lo) and THP-1Blue-CD14 (CD14hi). Briefly, at
conclusion of the experiment, conditioned medium was harvested
and incubated with Quantiblue colorimetric reagent (Autogen
Bioclear, Calne, UK) for 30 minutes at 37uC/5% CO2. Colori-
metric development was then measured spectrophotometrically by
an OPTIMax tuneable microplate reader at 620 nm and analysed
by Softmax Pro version 2.4.1 software. The resulting colour
development was directly proportional to the reporter gene SEAP
expression and hence NFkB activity.
Statistical analysis
Measure of statistical significance was analysed using a balanced
analysis of variance (General Linear Model, Minitab version 16)
followed by a multiple comparison test (LSD, least significant
difference). Significance was set at p,0.05 (*p,0.05, **p,0.01
and ***p,0.001).
Results
PG-LPS and HKPG induce separate pro-inflammatory
cytokine profiles in M1 and M2 MWs
Upon stimulation M1 and M2 MW subsets produce different
cytokine profiles; M1 MWs exhibit a predominantly pro-inflam-
matory cytokine profile whereas M2 MWs express a more anti-
inflammatory or regulatory profile. This experiment was under-
taken to establish whether M1 and M2 MWs responded similarly
to challenge with the oral pathogen, P.gingivalis. Indeed, PG
induced distinct cytokine profiles in M1 and M2 MWs. Stimulation
of these MW subsets was comparable, however, when stimulated
by either HKPG or PG-LPS: PG-LPS induced M1 expression of
the pro-inflammatory cytokines TNFa, IL-1b and IL-6 at a ratio
of 99:2:1. On the other hand, PG-LPS induced a TNFa: IL-1b:
IL-6 ratio in M2 MWs of 4:2:1, where the cytokine expression
between these two MW subsets was significant to p= 0.0098 for
TNFa, p = 0.046 for IL-1b and p=0.062 for IL-6 (Figure 1a, b &
c). A similar cytokine profile was observed when M1 and M2 MWs
were stimulated by HKPG. HKPG induced an M1 expression
profile of 249:8:1 and 10:12:1 in M2 MWs, where the cytokine
expression between these two MW subsets was significant to
p= 0.0008 for TNFa, p = 0.044 for IL-1b and p= 0.033 for IL-6
(Figure 1d, e & f). As a consequence of heterogeneity of CD14
expression on M1- and M2-like macrophages, IL-10 secretion was
not routinely detectable above the lower limit of detection of the
IL-10 ELISA, and as such was not presented in this figure. IL-10
secretion however, was detectable when examining a more
homogenous CD14hi and CD14lo macrophage population (refer
to later stable transfectant data figures and tables).
In addition, these THP-1 derived macrophage subsets both
display a differential response towards the enteropathic E. coli K12
LPS and the oral pathogenic P. gingivalis LPS. In agreement with
other studies [8], PG-LPS exhibits low endotoxin activity when
compared with the same concentration of K12-LPS. In the case of
M1 and M2 MWs, endotoxin activity was determined by the
strength of induction of TNFa secretion; PG-LPS resulted in 13%
TNFa induction in M1s compared to K12-LPS whereas in the
case of M2 MWs, PG-LPS resulted in 25% TNFa induction. This
may be consistent with PG-LPS utilisation of TLR2, as TNFa
induction was closer in amplitude to that of the TLR2 agonist,
LTA (see table 1).
P. gingivalis differentially suppresses M1 and M2 MW pro-
inflammatory cytokines
Macrophage challenge with Porphyromonas gingivalis (PG-LPS and
HKPG) differentially suppresses MW subset cytokine production
upon stimulation with the same pre-treatment challenges. Pre-
treatment of M1 pro-inflammatory MWs fails to suppress TNFa,
IL-1b and IL-6 when later challenged by PG-LPS and HKPG (see
figure 2a, b & c). M2-like MWs, on the other hand, were sensitive
to tolerance induction. PG-LPS pre-treatment strongly suppressed
M2 production of TNFa, upon stimulation with either PG-LPS
(reduced by 94%, p= 0.0383) or HKPG (reduced by 66%,
p= 0.0032) (See fig. 2d). Pre-treatment with HKPG partially
suppressed TNFa production stimulated by HKPG (reduced by
9%, p= 0.258) but clearly suppressed PG-LPS induced TNFa
(reduced by 92%, p= 0.0433) (see fig. 2d). In addition to PG-LPS
tolerising TNFa production to PG-LPS stimulation and HKPG
tolerising HKPG stimulation, these data also demonstrate a level
of cross-tolerisation between HKPG and PG-LPS with respect to
TNFa production by M2 MWs. M2 production of IL-1b, however,
failed to show any significant suppression in response to both pre-
treatment and stimulation by either HKPG or PG-LPS (fig. 2e).
IL-6 production, on the other hand, was partially suppressed,
dependent on pre-stimulation and challenge stimulus. Pre-
treatment with HKPG partially suppressed IL-6 production
stimulated by HKPG (reduced by 57%, p= 0.0067) but clearly
suppressed PG-LPS induced IL-6 (reduced by 79%, p= 0.0078)
(see fig. 2f). Pre-treatment with PG-LPS failed to suppress IL-6
production stimulated by HKPG, but clearly suppressed PG-LPS
induced IL-6 (by 48%, p= 0.0013) (fig. 2f).
PG-LPS and HKPG induction of pro-inflammatory
cytokine profiles in M1 and M2 MWs is CD14-dependent
In the homeostatic, regulatory mucosal environment, mucosal
MWs exhibit an M2-like phenotype characterised by a regulatory
cytokine profile and the absence of surface markers such as CD14
and CD89. The inflammatory environment results in recruitment
Table 1. PG-LPS exhibits weak endotoxin activity in THP-1-
derived macrophages.
Treatment M1-like macrophages M2-like macrophages
Control 9.067.6 7.060.0
LTA 347692 13296141
K12-LPS 51076775 28576480
PG-LPS 643679 704636
THP-1-derived M1-like (PMA) and M2-like (Vit D3) MWs were either unstimulated
(control) or stimulated with 100 ng/ml PG-LPS, 100 ng/ml E. coli K12 LPS (TLR4)
or 10 mg/ml LTA (TLR2) for 18 hours. Endotoxin activity was investigated by
TNFa secretion, presented as the mean 6 SD in pg/ml. Data displayed is
representative of triplicate samples for n = 3 replicate experiments.
doi:10.1371/journal.pone.0067955.t001
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of CD14+ monocytes, which differentiate to a CD14hi inflamma-
tory phenotype, resembling M1-like MWs. In an attempt to mimic
mucosal MWs in both homeostatic and inflamed tissue, the pro-
inflammatory cytokine profiles of M1 and M2 MWs, in response to
stimulation by HKPG and PG-LPS, was investigated for CD14lo
and CD14hi transfectant MWs. These CD14lo and CD14hi MWs
exhibited subtle changes in pro-inflammatory cytokine expression:
M1 & M2 CD14lo MWs display different amplitudes of cytokine
expression compared with CD14hi MWs in response to PG-LPS
and HKPG. When stimulated by PG-LPS, M1 CD14hi MWs
Figure 2. P.gingivalis differentially suppresses M1 & M2 MW cytokines. M1 (a, b & c) and M2 (d, e & f) MW subsets were pre-stimulated
(tolerised) with either 100 ng/ml PG-LPS (unshaded) or 16107 cells/ml HKPG (shaded) for 24 hours prior to stimulation with PG-LPS or HKPG and
incubated for a further 18 hours (untolerised controls indicated in bold). Cytokine production is expressed as the mean 6 SD in pg/ml for TNFa (a &
d), IL-1b (b & e) and IL-6 (c & f). Data displayed represents triplicate samples for n = 3 replicate experiments. Significant effects compared to the un-
tolerised stimulus control (bold) for the indicated MW subset are indicated as *p,0.05, **p,0.01 and ns, not significant.
doi:10.1371/journal.pone.0067955.g002
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expressed higher levels of TNFa, IL-1b and IL-6 at a ratio of
2.6:0.7:1.0, respectively) compared to M1 CD14lo MWs which
produced a ratio of 0.34:0.17:1.0, where the cytokine expression
between these two macrophage subsets was significant to
p= 0.0012 for TNFa, p = 0.0001 for IL-1b and p= 0.0019 for
IL-6 (Figure 3a, b & c). Conversely, the opposite expression was
observed with M2 MWs: M2 CD14lo MWs expressed greater levels
of TNFa, IL-1b and IL-6 at a ratio of 0.43:5.0:1.0 respectively
compared to that of M2 CD14hi MWs 0.21:3.0:1.0, where the
cytokine secretion between these two MW subsets was significant to
p= 0.0013, p = 0.0039, and p= 0.0002, respectively) (figure 3a, b
and c). This same cytokine profile was reproduced for CD14hi/
CD14lo M1 and M2 subsets when stimulated with HKPG, where
CD14hi M1 produced higher levels of TNFa (p = 0.0147), IL-1b
(p = 0.004) and IL-6 (p = 0.0003) when compared to CD14lo M1
MWs and conversely, CD14lo M2 MWs produced higher levels of
TNFa (p = 0.0007), IL-1b (p = 0.061) and IL-6 (p= 0.0033)
compared to CD14hi M2 cells (figure 3e, f and g). Finally, a
similar profile of production for the anti-inflammatory cytokine,
IL-10, was observed. CD14lo/hi M1 MWs produced similar low
levels when stimulated by PG-LPS (4365 and 4262 pg/ml) and
HKPG (4262 and 4161 pg/ml), respectively. M2 regulatory
MWs however, exhibited a differential induction of IL-10 in
response to PG stimulation. CD14lo M2 MWs produced 7463 and
12464 pg/ml in response to PG-LPS and HKPG, whereas
CD14hi M2s produced appreciably lower levels of IL-10 (961 and
3661 pg/ml), respectively (figure 3d and h).
As with the case of non-transfected THP1-derived macrophage
subsets, PG-LPS demonstrated a weak endotoxin activity when
compared to E. coli K12-LPS-induction of TNFa in stably
transfected CD14hi/lo M1/M2 macrophages. PG-LPS endotoxin
activity was 5%, 16%, 8% and 4% that of K12-LPS induction of
TNFa by CD14lo M1, CD14hi M1, CD14lo M2 and CD14hi M2,
respectively (see table 2).
PG-LPS and HKPG induce differential NFkB activation
amplitudes in CD14hi/CD14lo M1 and M2 MWs
MW production of the pro-inflammatory cytokines TNFa, IL-
1b and IL-6 has been described to be dependent on the
transcription factor, NFkB. The previous section demonstrated
the ability of PG-LPS and HKPG to induce these cytokines in a
subset-specific manner; considering NFkB -dependence of these
cytokines, it was essential to investigate whether P. gingivalis also
induced activation of this signalling component. Indeed, M1 and
M2 MW activation of NFkB was found to be determined by both
differentiation and CD14 expression. In line with the cytokine
expression data previously, CD14lo and CD14hi MWs demon-
strated differential NFkB activity responses when stimulated by
HKPG and PG-LPS. In the case of the pro-inflammatory M1-like
MWs, M1 CD14lo expressed lower NFkB activation than M1
CD14hi MWs (lower than CD14hi by 75% and 62% for HKPG
(p= 0.0013) and PG-LPS (p = 0.0033), respectively) (Figure 4a).
The opposite trend is observed for M2-like MWs: M2 CD14lo
expressed higher NFkB activation than M2 CD14hi MWs (higher
than CD14hi by 117% and 96% for HKPG (p= 0.014) and PG-
LPS (p= 0.0053), respectively) (Figure 4b). This differential profile
of NFkB activation, parallels that observed for P. gingivalis
induction of TNFa by all of the CD14hi/lo M1/M2 MW subsets,
suggestive of a direct link between NFkB activation and MW
production of these pro-inflammatory cytokines.
P. gingivalis differentially suppresses CD14hi/lo M1 and M2
MW NFkB activity, TNFa and the anti-inflammatory
cytokine, IL-10
Previous data in this manuscript have demonstrated that PG-
LPS and HKPG activation of NFkB and induction of the NFkB -
dependent pro-inflammatory cytokines are differentially regulated
in M1 and M2 MW subsets and amplitudes dependent on CD14
expression. Preliminary investigation of PG-induced tolerance/
suppression demonstrated that M2 MWs were sensitive to
suppression whereas M1 MWs were refractory. These THP-1-
derived MW subsets are heterogenous with respect to their CD14
expression; mucosal MWs however, demonstrate distinct CD14
profiles where tolerogenic/homeostatic mucosal MWs are CD14lo
and are analogous to an M2 phenotype whereas inflammatory
invasive MWs are CD14hi and resemble the pro-inflammatory M1
subset [23,28,29]. As a consequence of this, the ability of PG to
induce tolerance/suppression in both CD14lo and CD14hi MW
subsets, in the context of pro-inflammatory TNFa production and
NFkB activation, was investigated.
M2 MWs were observed to be sensitive to tolerisation and cross-
tolerisation by both PG-LPS and HKPG with respect to NFkB
activation. CD14lo and CD14hi M2 MW NFkB activation were
totally suppressed to unstimulated control levels, upon pre-
treatment with these PG PAMPs (figure 5c and 5d). The pro-
inflammatory MW subset however, was differentially sensitive to
tolerance induction by PG. The CD14hi M1 phenotype of MW,
(representative of invasive, recruited pro-inflammatory MWs) was
refractory to tolerance induction by both PG-LPS and HKPG
(figure 5b) whereas CD14lo M1 MWs were sensitive to pre-
treatment suppression. PG-LPS stimulation control levels of NFkB
activation were suppressed by 60% and 48% upon pre-treatment
with PG-LPS and HKPG, respectively, whereas HKPG stimula-
tion control was suppressed by 66% and 78%, respectively (refer to
figure 5a).
The induction of TNFa production by these MW subsets
displayed the same tolerance sensitivity profile as presented with
NFkB activation (refer to figure 6). CD14lo and CD14hi M1 & M2
MWs exhibited different sensitivities to PG PAMP tolerisation and
cross-tolerisation. In general, PG-LPS and HKPG-stimulation of
TNFa production was suppressed upon pre-treatment with both
the same PAMP (PG-LPS pre-treatment followed by PG-LPS
stimulation and HKPG pre-treatment followed by HKPG
stimulation) and the alternative PAMP (PG-LPS pre-treat, HKPG
stimulus and HKPG pre-treat, PG-LPS stimulus). This suppres-
sion or tolerisation was clearly evident in both CD14hi and CD14lo
M2 MWs (figure 6c, 6d) and less so in the case of CD14lo M1 MWs
where PG-LPS stimulation control levels were suppressed by 72%
and 74% upon pre-treatment with PG-LPS and HKPG,
respectively, whereas HKPG stimulation control was suppressed
by 66% and 75%, respectively (figure 6a). In contrast, HKPG and
PG-LPS failed to suppress HKPG and PG-LPS-stimulated TNFa
production by the pro-inflammatory CD14hi M1 MW subset
(figure 6b).
In addition, the anti-inflammatory cytokine, IL-10, also
demonstrated a distinct tolerisation profile in response to HKPG
and PG-LPS. Both of these P. gingivalis products exhibited both
homo- and hetero-tolerisation of IL-10 secretion. Suppression of
IL-10 was clearly demonstrated for both CD14lo and CD14hi M2
MWs (figure 7c and d) where, irrespective of pre-treatment and
stimulus combination, P. gingivalis suppressed CD14lo M2 IL-10 by
70 to 85% and CD14hi M2 MWs by 34 to 78%. Interestingly, this
pattern of tolerisation was extended to the pro-inflammatory
CD14hi M1 MWs (figure 7b), where PG-LPS and HKPG
suppressed IL-10 production between 68 to 76%, and less so the
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degree of suppression in the CD14lo M1subset 23 to 44%
suppression of P. gingivalis stimulus (figure 7a).
This tolerisation-sensitivity profile of these distinct MW subsets
was reproduced when investigating other NFkB -dependent pro-
inflammatory cytokines such as IL-1b and IL-6. Table 3 highlights
the ability of PG-LPS and HKPG as well as the TLR2 PAMP,
LTA, to tolerise and cross-tolerise these pro-inflammatory
cytokines (TNFa, IL-1b and IL-6). What is evident from this
table is that PG-LPS, HKPG and LTA-induced cytokines are
sensitive to suppression by pre-treatment with PG-LPS, HKPG
and LTA: as with figures 5 and 6, the CD14hi M1 MW subset was
found to be refractory to tolerance induction when compared to
the other subsets and that there was a preferential cytokine
sensitivity to suppression where, in general, TNFa was the most
sensitive and IL-1b the least sensitive to suppression (refer to
table 3).
Peptidoglycan differentially cross-tolerises P. gingivalis-
stimulated macrophage subsets
Cross-tolerisation has been described between different micro-
bial species, their PAMPs and the corresponding PRRs, which
may have a role to play in the inflammatory process of CP, which,
in addition to P. gingivalis, is generally driven by a collection of oral
pathogens. In addition to the suggestion of cross-tolerisation
exhibited between HKPG, PG-LPS and LTA and the differing
suppression observed between these PAMPs in the previous table,
it was desirable to investigate this process with respect to the
bacterial cell wall PAMP, peptidoglycan (PGN). In contrast to PG-
LPS, HKPG and LTA tolerisation, PGN exhibits a different
pattern of macrophage tolerisation. PGN tolerisation, in general,
resulted in a higher level of suppression of the pro-inflammatory
cytokines (TNFa, IL-1b, IL-6) and the anti-inflammatory cytokine,
IL-10, in all the CD14hi/lo M1/M2 subsets when compared to
P.gingivalis and LTA tolerisation. The most striking result however,
was the observation that CD14lo M1 MWs were refractory (3%
and 0% suppression) to tolerisation of IL-6 response, whereas
CD14hi M1 and M2 MWs exhibited a high level of suppression.
Finally, PGN-induced suppression of NFkB activity was weakest in
both CD14hi M1 and M2 macrophages (refer to table 4).
Discussion
This investigation has resulted in several conclusions being
drawn with respect to MW responses to the oral pathogen,
Porphyromonas gingivalis. Firstly, the PAMP-induced profile of pro-
inflammatory cytokine production is dependent on both the route
Figure 3. PG-LPS and HKPG induction of M1 and M2 MW pro-inflammatory cytokines are CD14-dependent. THP-1-derived CD14-high-
and CD14-low-expressing (CD14hi and CD14lo) M1 and M2 MWs were generated by differentiating CD14+ and CD142 stable transfectant THP-1-blue
monocytes with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1,25-(OH)2 vitamin D3 for 7 days, respectively. CD14
hi/
CD14lo M1 (bold) and M2 (shaded) MW subsets were stimulated with either 100ng/ml PG-LPS (a, b, c & d) or 16107 cells/ml HKPG (e, f, g & h). Cytokine
production is expressed as the mean 6 SD in pg/ml for TNFa (a & e), IL-1b (b & f), IL-6 (c & g) and IL-10 (d & h). Data displayed represents triplicate
samples for n = 3 replicate experiments. Significant differences in cytokine production between activated CD14hi and CD14lo MWs are indicated as
*p,0.05, **p,0.01, ***P,0.001 and ns, not significant.
doi:10.1371/journal.pone.0067955.g003
Table 2. PG-LPS exhibits weak endotoxin activity in CD14hi/lo
M1/M2 macrophages.
Treatment CD14lo M1 CD14hi M1 CD14lo M2 CD14hi M2
Control 7.060.0 7.060.0 7.060.0 7.060.0
LTA 420616 19006535 554643 802650
K12-LPS 38276195 548361657 17436361 618643
PG-LPS 19369.0 8616223 13267.0 2661.0
THP-1-derived CD14-high- and CD14-low-expressing (CD14hi and CD14lo) M1
and M2 MWs were either unstimulated (control) or stimulated with 100 ng/ml
PG-LPS, 100 ng/ml E. coli K12 LPS (TLR4) or 10 mg/ml LTA (TLR2) for 18 hours.
Endotoxin activity was investigated by TNFa secretion, presented as mean6 SD
in pg/ml. Data displayed is representative of triplicate samples for n = 3
replicate experiments.
doi:10.1371/journal.pone.0067955.t002
Figure 4. P. gingivalis activation of M1 & M2 MW induces
differential CD14-dependent NFkB amplitudes. CD14lo (bold)
and CD14hi (shaded) M1 and M2 MW subsets were stimulated with
either 100 ng/ml PG-LPS or 16107 cells/ml HKPG. NFkB activation is
expressed as the mean absorbance units A620nm6 SD for M1 (a) and M2
(b) MW subsets. Data displayed represents triplicate samples for n= 3
replicate experiments. Significant differences in NFkB activation
between CD14hi and CD14lo MWs are indicated as *p,0.05, **p,0.01
and ns, not significant.
doi:10.1371/journal.pone.0067955.g004
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of MW differentiation and the level of expression of the co-
receptor, CD14. In general, M1-like MWs were characterised as
TNFahi, IL-1blo, IL-6lo whereas M2-like MWs were TNFalo, IL-
1bhi and IL-6hi. With respect to the induction of the anti-
inflammatory cytokine, IL-10, CD14hi/lo M1 macrophages exhib-
ited low-level expression of IL-10 whereas higher expression was
restricted to the CD14lo M2 subset. Secondly, these MWs
displayed differential sensitivities to tolerance induction by both
P. gingivalis-derived bacterial PAMPs and the TLR2 ligand, LTA
ie. direct homo- and cross-/hetero-tolerance. P. gingivalis induced
suppression of inflammatory cytokines in the CD14lo/hi M2- and
CD14lo M1-like subsets, whereas, the pro-inflammatory CD14hi
M1-like subset was refractory to tolerance induction. Finally, this
MW pro-inflammatory cytokine tolerisation profile appeared to be
linked to sensitivity to suppression of the pro-inflammatory
transcription factor, NFkB.
Irrespective of stimulation, the M1 and M2 subsets displayed
differing cytokine effector profiles: M1 MWs exhibited a pro-
inflammatory phenotype (TNFahi, IL-1blo, IL-6lo, IL-10lo) where-
as M2 MWs were less inflammatory and tending to anti-
inflammatory/regulatory when compared to M1s (TNFalo, IL-
1bhi, IL-6hi, IL-10+). In line with characteristic mucosal MW
phenotypes, CD14 expression determined M1 and M2 cytokine
amplitudes and NFkB activation resulting from P. gingivalis
stimulation. CD14hi M1 MWs (representative of recruited, pro-
inflammatory pathological MWs) was described as TNFahi, NFkB
hi whereas the CD14lo M1subset was TNFalo, NFkB lo. On the
other hand, CD14lo M2s (representative of regulatory, anti-
inflammatory mucosal MWs) were TNFalo, NFkB med and CD14hi
M2s were TNFalo, NFkBlo. Contrary to our understanding of pro-
inflammatory and anti-inflammatory MW subsets, M2-like MWs
produce higher levels of both IL-6 and IL-1b in response to PG-
LPS and HKPG. These two cytokines, although thought of as pro-
inflammatory, exhibit clear anti-inflammatory properties. IL-6
exerts its anti-inflammatory effects through induction of SOCS
proteins and STAT-3 activation [30] and reviewed in [31].
Indeed, SOCS-3 is associated with M1 classical MW polarisation
and is suppressive to anti-inflammatory signal and expression of
IL-6 and IL-10. Conversely, SOCS-3 expression knockdown
favours M2 polarisation [32]. Thus, the reciprocal relationship
between SOCS-3 and STAT-3 would appear to regulate pro- or
anti-inflammatory effect of IL-6 and the polarisation of MWs
between M1 and M2 effector subsets. IL-1b, on the other hand,
may mediate anti-inflammatory responses via its ability to induce
IL-10 expression [33]; indeed, results from this study are
suggestive of a positive correlation between IL-1b and IL-10, as
these cytokines are produced strongest by the CD14lo anti-
inflammatory/regulatory M2 macrophages. In addition, IL-1b
secretion has been demonstrated to be negatively associated with
the pro-inflammatory IKKb-dependent NFkB pathway [34];
Figure 5. P. gingivalis differentially suppresses CD14hi/lo M1 and M2 MW NFkB activity. CD14lo M1 (a) CD14hi M1 (b), CD14lo M2 (c) and
CD14hi M2 (d) MW subsets were pre-stimulated (tolerised) with either 100 ng/ml PG-LPS (unshaded) or 16107 cells/ml HKPG (shaded) for 24 hours
prior to stimulation with PG-LPS or HKPG and incubated for a further 18 hours (untolerised controls indicated in bold). NFkB activation is expressed
as the mean absorbance units A620nm 6 SD for the CD14
hi/lo M1 and M2 MW subsets. Data displayed represents triplicate samples for n = 3 replicate
experiments. Significant effects compared to the un-tolerised stimulus control (bold) for each MW subset are indicated as *p,0.05, ***p,0.001 and
ns, not significant.
doi:10.1371/journal.pone.0067955.g005
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suggestive of a non-pro-inflammatory role for IL-1b and the
complex wiring of the NFkB pathway in determining cell effector
phenotype. Modulation of effector phenotype would thus play an
important role in determining whether responses initiated in the
oral mucosa are pro-inflammatory, destructive or anti-inflamma-
tory, tolerogenic. Specific modulation of such subsets would
directly affect pathogenic mechanisms associated with pathogens
infecting the oral mucosa.
Mucosal MWs are considered to exist in discrete functional
subsets, governed by the environment that exists in the mucosal
tissue itself. In homeostatic conditions, mucosal MWs fail to express
CD14 and express a functional phenotype resembling the
regulatory, anti-inflammatory M2 subset [23,28,29]. Upon mu-
cosal dysfunction, barrier breakdown and inflammatory patholog-
ical conditions, these tolerogenic MWs change their effector
phenotype to a predominantly pro-inflammatory M1-like subset.
Manipulation of MW effector phenotype via controlling mono-
cyte/MW infiltration into the mucosa, plasticity between M1 and
M2 subsets, or indeed specific MW subset tolerance induction
would be of great benefit for future therapeutic management of
such inflammatory pathologies as chronic periodontitis. In the
context of mucosal MWs, whether CD14 expression is integral to
tolerance induction or is just reflective of a tolerisable sensitive
subset is not proven. CD14 is known to be co-expressed with both
TLR2 and TLR4, both of which can be utilised by P.gingivalis. PG-
LPS is generally recognised as transducing its signal through
TLR2. Data presented in this study suggested that P. gingivalis and
PAMPs derived from other microbes which signal through
different PRRs, induce cross-tolerance, whereby peptidoglycan
(which signals through NOD2) differentially tolerised both PG-
LPS and HKPG (TLR2)-induced macrophage cytokines. In line
with other published studies, it is probable that PAMPs such as E.
coli-K12 LPS (gram-negative bacterial PAMP signalling through
TLR4) are able to differentially suppress M1 and M2 responses to
gram-positive bacteria and signals transduced through both TLR2
(homo-tolerance) and non-TLR2 (hetero- or cross-tolerance)
PRRs such as TLR4 and NOD2 [35–37].
The fact that CD14hi M1 pro-inflammatory MWs were
refractory to tolerance-induction by HKPG and PG-LPS suggest-
ed that MW tolerance sensitivity was, in part, dependent on CD14.
This was observed for both pro-inflammatory cytokine production
(TNFa, IL-1b and IL-6) and NFkB, whereas IL-10 was suppressed
Figure 6. P. gingivalis differentially suppresses CD14hi/lo M1 and M2 MWs TNFa production. CD14lo M1 (a) CD14hi M1 (b), CD14lo M2 (c)
and CD14hi M2 (d) MW subsets were pre-stimulated (tolerised) with either 100 ng/ml PG-LPS (unshaded) or 16107 cells/ml HKPG (shaded) for
24 hours prior to stimulation with PG-LPS or HKPG and incubated for a further 18 hours (untolerised controls indicated in bold). Pro-inflammatory
TNFa cytokine production is expressed in pg/ml as the mean 6 SD for the CD14hi/lo M1 and M2 MW subsets. Data displayed represents triplicate
samples for n = 3 replicate experiments. Significant effects compared to the un-tolerised stimulus control (bold) for each MW subset are indicated as
***p,0.001 and ns, not significant.
doi:10.1371/journal.pone.0067955.g006
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in these macrophages; suggesting that tolerance-induction was
only partially dependent on NFkB activity and CD14 expression.
Several mechanisms have been described which are involved in
ET of NFkB -dependent readouts. These include the up-
regulation of endogenous suppressors of NFkB activation such as
SIGIRR, ST2, A20, Myd88 s and IRAK-M [9,38]. NFkB is also
important with respect to MW subset polarisation; IkBa over-
expression resulted in M2 polarisation [19], whereas IKKb
deletion favoured M1 MWs [20]. Thus, M1 subset polarisation is
dependent on the classical p65/p50 NFkB heterodimer and M2
polarisation was found to be dependent on the alternative NFkB
p50/p50 homodimer [21]. Manipulation of such classical and
alternative NFkB pathways is likely to have a dramatic influence
on MW plasticity, hence determining immune response as either
pro-inflammatory/immune activatory or anti-inflammatory/tol-
erogenic.
Stimulation and pre-stimulation protocols investigate tolerisa-
tion by PG-LPS and HKPG, allowing the study of signals via
PRRs but does not consider soluble/secreted immunomodulatory
components produced by live bacteria. P.gingivalis secretes
gingipains which are involved in endotoxin tolerance by cleavage
of CD14 from the cell surface, leading to LPS hypo-responsiveness
[24], either through CD14 absence from the LPS-binding receptor
complex or through secreted CD14 competing for the LPS/LBP
complex, hence antagonising the LPS-TLR signal, reviewed in [9].
It is probable that these gingipains may also induce ET through
the shedding of PRRs such as TLR4, TLR2 and TLR5. In
addition, this induction of ET may also be mediated via a
protease-mediated shedding of both membrane-bound TNFa and
its receptor, TNF-Rp75 [39]; hence suppression of TNFa-
mediated inflammatory responses.
Chronic periodontitis is not just driven by P. gingivalis alone. To
appreciate all the underlying pathological mechanisms, the
complex interactions between the host immune factors and the
microbial ecosystem of oral commensal and pathogenic bacteria
requires investigation. Indeed, CP is characterised by bacterial
plaque formation; it is likely these complex bacterial biofilms play
a significant role in protecting pathogens from host immune
responses either as a consequence of inaccessibility to damaging
immune responses or through the regulation/deviation of these
defences. One such intriguing pathogen response to host immunity
by PG biofilms was found to be via the degredation of both pro-
Figure 7. P. gingivalis differentially suppresses CD14hi/lo M1 and M2 MW IL-10 production. CD14lo M1 (a) CD14hi M1 (b), CD14lo M2 (c) and
CD14hi M2 (d) MW subsets were pre-stimulated (tolerised) with either 100 ng/ml PG-LPS (unshaded) or 16107 cells/ml HKPG (shaded) for 24 hours
prior to stimulation with PG-LPS or HKPG and incubated for a further 18 hours (untolerised controls indicated in bold). Anti-inflammatory IL-10
cytokine production is expressed in pg/ml as the mean 6 SD for the CD14hi/lo M1 and M2 MW subsets. Data displayed represents triplicate samples
for n= 3 replicate experiments. Significant effects compared to the un-tolerised stimulus controls (bold) for each MW subset are are indicated
as*p,0.05, **p,0.01, ***p,0.001 and ns, not significant.
doi:10.1371/journal.pone.0067955.g007
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inflammatory (IL-1b, IL-6) and anti-inflammatory (IL-1Ra)
cytokines [40]. Such an immuno-suppressive mechanism was
again indicative of microbial protease activity.
The significance of these data in the context of CP is difficult to
interpret. In general, any mechanism, which induces tolerance is
likely to be beneficial to chronic pathologies that result from over-
exuberant immune responses. These data clearly demonstrate a
Table 3. CD14hi/lo M1 and M2 MW cytokines are differentially tolerised by P.gingivalis and LTA PAMPs.
Tolerisation
signal Stimulus
Cytokine
induced CD14lo M1 CD14hi M1 CD14lo M2 CD14hi M2
PG-LPS PG-LPS
HKPG
LTA
TNFa 72.063.0
65.561.0
97.761.0
22.763.2
23.0612.3
53.763.4
94.760.0
97.760.0
98.460.0
73.060.0
93.760.0
96.660.0
PG-LPS
HKPG
LTA
IL-1b 0.064.5
37.063.3
0.062.0
0.068.1
0.067.5
0.0610.7
56.462.1
87.860.3
91.260.2
70.661.2
89.362.1
94.760.3
PG-LPS
HKPG
LTA
IL-6 36.664.4
0.064.3
26.462.1
3.063.5
0.0611.1
4.162.9
46.267.1
82.261.0
87.660.2
62.460.5
85.961.0
95.260.1
HKPG PG-LPS
HKPG
LTA
TNFa 73.462.9
74.861.7
91.661.7
0.067.5
23.069.4
0.062.6
94.760.0
97.760.0
98.460.0
73.060.0
93.760.0
96.660.0
PG-LPS
HKPG
LTA
IL-1b 0.0610.8
27.761.7
0.061.6
0.064.3
0.0614.5
0.062.3
35.8619.9
85.260.2
75.961.7
52.261.3
83.264.4
88.360.7
PG-LPS
HKPG
LTA
IL-6 48.367.3
0.063.6
15.963.1
0.062.4
0.065.8
0.061.8
46.868.8
82.961.1
77.560.7
42.363.3
75.764.6
90.160.1
LTA PG-LPS
HKPG
LTA
TNFa 31.564.9
14.064.1
30.265.0
2.961.6
18.360.8
0.863.9
94.760.0
97.760.0
98.560.0
73.160.0
93.760.0
96.660.0
PG-LPS
HKPG
LTA
IL-1b 18.462.9
59.561.7
31.662.1
0.063.6
0.067.0
23.4610.8
76.961.0
86.660.9
88.660.3
71.961.3
88.260.3
88.360.7
PG-LPS
HKPG
LTA
IL-6 38.162.3
0.061.9
29.462.5
34.762.1
14.964.2
2.964.8
68.762.3
77.760.6
77.560.7
58.860.0
77.361.6
90.160.1
CD14hi/lo M1 and M2 MW subsets exhibit a differential tolerisation and cross-tolerisation of cytokine production to the P gingivalis PAMPs, PG-LPS and HKPG as well as
the TLR2 PAMP, lipoteichoic acid (LTA). CD14lo M1, CD14hi M1, CD14lo M2 and CD14hi M2 MW subsets were pre-stimulated (tolerised) with either 100 ng/ml PG-LPS,
16107 cells/ml HKPG or 10 mg/ml LTA for 24 hours prior to stimulation with PG-LPS, HKPG or LTA and incubated for a further 18 hours. Tolerisation/suppression of the
pro-inflammatory cytokines, TNFa (also refer to graphs in figure 6), IL-1b and IL-6 is expressed as the mean percentage suppression 6 SD of non-tolerised stimulation
controls. Data displayed represents triplicate samples for n = 3 replicate experiments.
doi:10.1371/journal.pone.0067955.t003
Table 4. Peptidoglycan differentially cross-tolerises P. gingivalis-stimulated CD14hi/lo M1 and M2 MW subsets.
Tolerisation
signal Stimulus Mediator CD14lo M1 CD14hi M1 CD14lo M2 CD14hi M2
PGN PG-LPS
HKPG
NFkB 24.863.8
23.461.5
13.362.1
9.061.7
31.861.8
19.665.7
15.568.2
4.463.4
PG-LPS
HKPG
TNFa 74.260.5
74.160.8
39.465.3
85.862.9
96.360.5
97.560.9
70.8650.5
91.266.1
PG-LPS
HKPG
IL-1b 20.762.4
70.861.2
77.3618.0
46.664.3
80.661.2
87.260.9
40.763.8
70.562.3
PG-LPS
HKPG
IL-6 3.363.1
0.060.0
63.861.3
75.260.4
84.960.5
94.760.3
59.760.8
85.660.9
PG-LPS
HKPG
IL-10 46.562.3
40.562.4
64.360.0
46.3611.2
78.461.4
87.160.0
48.266.4
69.5612.1
CD14hi/lo M1 and M2 MW subsets exhibit a differential cross-tolerisation of cytokine production and NFkB activity to the P gingivalis PAMPs, PG-LPS and HKPG. CD14lo
M1, CD14hi M1, CD14lo M2 and CD14hi M2 MW subsets were pre-stimulated (tolerised) with 10mg/ml peptidoglycan (PGN) for 24 hours prior to stimulation with PG-LPS
or HKPG and incubated for a further 18 hours. Tolerisation/suppression of the pro-inflammatory cytokines (TNFa, IL-1b and IL-6), the anti-inflammatory cytokine (IL-10)
and the transcription factor activity (NFkB) is expressed as the mean percentage suppression 6 SD of non-tolerised stimulation controls. Data displayed represents
triplicate samples for n = 3 replicate experiments.
doi:10.1371/journal.pone.0067955.t004
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role for PG in tolerance induction of M2 and CD14lo M1 MW-
inflammatory mediators, whereas no suppression was observed
with inflammatory CD14hi M1 MWs. This suggested some
beneficial effect to the oral pathogen by failing to suppress the
pro-inflammatory macrophage. Indeed, early P. gingivalis infection
events were found to be anti-inflammatory or tolerant, enabling
the pathogen to expand its numbers. This population expansion
leads to an increase in inflammatory mechanisms, resulting in
tissue destruction, lesions and a reduction in bacterial numbers. As
a consequence of this cycling in pathogen numbers; it is likely that
this relapsing/remitting chronic inflammatory disease is charac-
terised by immunopathological mechanisms constantly switching
between inflammation and tolerance/regulation. Maintenance of
this chronic cycling between ET and destructive inflammation
over a long period is detrimental to the host; long-term ET
rendering the host more susceptible to infection (immunocompro-
mised) and long-term inflammatory responses resulting in host
tissue destruction without pathogen clearance.
In conclusion, this investigation has further characterised M1-
and M2-like MW subsets with respect to pro-inflammatory
cytokine profile upon stimulation with P. gingivalis PAMPs. It
demonstrates a dichotomy in cytokine secretion where M1 MWs
are indeed the predominant pro-inflammatory cell. This effector
response was further elucidated in the context of subsets relevant
to mucosal MWs where, in response to P. gingivalis, the CD14lo M2
subset, representative of regulatory, anti-inflammatory cells, was
indeed a low-level producer of TNFa and IL-10+ whereas CD14hi
M1 MWs, representative of infiltrated pro-inflammatory patho-
logical cells, were predominantly pro-inflammatory and strongly
produced TNFa. This cytokine profile is likely to be as a
consequence of NFkB activation, as NFkB activation profile for
these MW subsets, closely paralleled the cytokine response. In
addition, upon investigation of sensitivity of these subsets to
tolerisation, it was observed that the subset least sensitive to P.
gingivalis-induced suppression of pro-inflammatory cytokines and
NFkB activation was the inflammatory pathology-related subset,
CD14hi M1. This would suggest that such mechanisms of ET may
be beneficial for survival and immunopathological mechanisms
driven by the pathogen. To conclude, any future manipulation of
MW subset suppression can only realistically be employed upon a
full understanding of the immunopathological mechanisms behind
such relapsing/remitting diseases as CP and by considering; who is
tolerance induction of benefit to….host or pathogen?
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